Introduction {#s1}
============

MicroRNAs (miRNAs) are small, single-stranded, 19--21 nucleotide long non-protein-coding RNA molecules, functioning as negative regulators that involve post-transcriptional gene expression through binding to their target mRNAs regions and consequently lead to mRNA cleavage or translational repression [@pone.0049032-Bartel1]. Accumulating evidence has shown that miRNAs regulate the expression of roughly 10--30% of the all human genes through post-transcriptional mechanisms [@pone.0049032-Berezikov1], contributing to excessive physiologic and pathologic conditions, including cell differentiation, proliferation, and apoptosis [@pone.0049032-Bartel1], and inparticular to the development and progression of various human cancers by regulating the expression of proto-oncogenes or tumor suppressor genes [@pone.0049032-Calin1], [@pone.0049032-Cho1], [@pone.0049032-Cho2].

SNPs in miRNA genes are regarded to affect function by three ways: first, through the transcription of the primary transcript; second, through pri-miRNA and pre-miRNA processing; and third, through effects on miRNA-mRNA interactions [@pone.0049032-Ryan1]. Recently, several studies have demonstrated that some polymorphism(SNPs) present in the miRNA genes, which can alter miRNA expression and/or maturation and be associated with the development and progression of cancer [@pone.0049032-Ryan1]. For example, four SNPs -- miR-196a2C\>T (or rs11614913), miR-146aG\>C (rs2910164), miR-499A\>G (rs3746444), and miR-149C\>T (rs2292832) -- identified in the pre-miRNA regions of miR-146a, miR-149, miR-196a2, and miR-499, respectively, have been reported to be associated with cancer risk [@pone.0049032-Xu1], [@pone.0049032-Horikawa1]. However, conclusions of the relevant studies remain inconsistent, in part because of heterogeneity of the cancer subtype, small sample size, and ethnicity of the patients. To further determine whether there is an association of the four SNPs in the miRNA genes with the risk for developing cancer, a comprehensive review and analysis of published data from different studies is needed. In this study, we have extensively reviewed literature and performed a meta-analysis based on all eligible case-control published data to evaluate the association between the four polymorphisms and cancer susceptibility.

Materials and Methods {#s2}
=====================

Identification of eligible studies {#s2a}
----------------------------------

We carried out a search of the PubMed and Embase databases for all relevant reports using the key words 'microRNA/miR-146a/miR-149/miR-196a2/miR-499', 'polymorphism', and 'cancer' (updated to Jun 23, 2012). The search was limited to English language papers and human subject studies. We evaluated potentially relevant publications by examining their titles and abstracts, thereafter all studies matching the eligible inclusion criteria were retrieved. In addition, studies were identified by a manual search of the references listed in the reviews involved. All the studies were included if they met the following criteria: (i) about the rs11614913, rs2910164, rs3746444, and rs2292832 polymorphisms and cancer risk, (ii) from a case--control designed study, and (iii) genotype frequencies available.

Data extraction {#s2b}
---------------

All data complying with the selection criteria were extracted independently by two staff (B.S.H., and Y.Q.X). For each study, the following characteristics were extracted: the first author\'s last name, year of publication, country of origin, ethnicity, the numbers of genotyped cases and controls, source of control groups (population- or hospital-based controls), genotyping methods and cancer type. Ethnic descents were categorized as Caucasian, Asian or mixed (which included more than one ethnic descent). One study included the information for genotype rs11614913 CT+TT, without the data for CT and TT genotypes, so we were only able to calculate the OR for the comparison between CT+TT vs. TT [@pone.0049032-Christensen1].

Statistical analysis {#s2c}
--------------------

The four SNPs in miRNAs were tested for the associations with cancer susceptibility based on different genetic models. The meta-analysis examined the overall association of the four SNPs with the risk of cancer as measured by odds ratios (ORs) at the 95% confidence intervals (CIs). To contrast the wild-type homozygote (WW), we first estimated the risk of the rare allele homozygote (RR) and heterozygous (WR) genotypes on cancers, then evaluated the risk of cancer under a dominant model (RR+WR vs. WW). In addition, recessive model associations were also estimated (RR vs. WR+WW). Moreover, stratified analyses were also performed by ethnicity (Asian, and Caucasian), cancer type (if only one cancer type contained fewer than two individual studies it was combined into the 'Other Cancers' group) and source of control for rs11614913 and rs2910164. Stratified analyses were performed by ethnicity for rs2292382, and by ethnicity and cancer type for rs3746444, respectively.

The statistical significance of the pooled OR was determined with the Z test, and a P value of \<0.05 was considered significant. The heterogeneity between studies was evaluated by the Chi-square based Q statistical test [@pone.0049032-Handoll1], with heterogeneity (*P* ~h~) \<0.05 being considered significant. A fixed-effect model using the Mantel--Haenszel method and a random-effects model using the DerSimonian and Laird method were used to pool the data [@pone.0049032-Midgette1]. The random-effects model was used when heterogeneity in the results of the studies was found; otherwise the fixed-effect model was used. Sensitivity analyses were performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the an individual data set on the pooled OR. To determine whether there was a publication bias, Funnel plots and Egger\'s linear regression tests were applied [@pone.0049032-Egger1].

All statistical tests for this meta-analysis were performed with STATA version 10.0 (Stata Corporation College Station, TX, USA).

Results {#s3}
=======

Characteristics of the studies {#s3a}
------------------------------

A total of 40 eligible studies met the prespecified inclusion criteria (See [Figure S1](#pone.0049032.s001){ref-type="supplementary-material"}), in which 27, 26, 13, and 6 studies were pooleded for the analyses of the rs11614913, rs2910164, rs37464444, and rs2292832, respectively ([Table 1](#pone-0049032-t001){ref-type="table"}). All studies were case-control studies, including 8 studies on hepatocellular cancer (HCC), 5 breast cancer, 5 gastric cancer, 4 colorectal cancer, 3 lung cancer, and 15 on other cancer types, and one on breast/ovarian cancer was enrolled. There were 28 studies of Asian descendent, 11 of Caucasian descendents and one of mixed ethnicity [@pone.0049032-Hoffman1]. To determine the SNPs, genotyping by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and TaqMan assay were performed in the 28 studies. In addition, 34 studies were included based on the control sex- and age-matched for the case groups (six studies with 2,050 cases and 2,626 controls were not matched by age or sex), of which 33 were population-based and seven were hospital-based.

10.1371/journal.pone.0049032.t001

###### Summary of published studies included.

![](pone.0049032.t001){#pone-0049032-t001-1}

          Author      Year     Race              Cancer type           Control           Method            Case/control              Polymorphism site
  ---- ------------- ------ ----------- ----------------------------- --------- ------------------------- -------------- ------------------------------------------
  1         Xu        2008     Asian                 HCC                 PB             PCR-RFLP             479/504                     rs2910164
  2         Hu        2008     Asian            Breast Cancer            PB             PCR-RFLP            1009/1093     rs11614913,rs2910164,rs3746444,rs2292832
  3     Jazdzewski    2008   Caucasian   Papillary thyroid carcinoma     PB              SNPshot             608/901                     rs2910164
  4         Ye        2008   Caucasian        Esophageal Cancer          PB           SNPlex assay           307/388                rs11614913,rs2910164
  5      Horikawa     2008   Caucasian      Renal cell carcinoma         PB           SNPlex assay           276/277                rs11614913,rs2910164
  6        Tian       2009     Asian             Lung Cancer             PB             PCR-RFLP            1058/1035     rs11614913,rs2910164,rs3746444,rs2292832
  7       Hoffman     2009      mix             Breast Cancer            HB            iPLEX GOLD            426/466                     rs11614913
  8         Xu        2010     Asian           Prostate Cancer           PB             PCR-RFLP             251/280                     rs2910164
  9         Yoo       2010     Asian             lung cancer             PB      melting-curve analysis      654/640                     rs11614913
  10        Guo       2010     Asian          Esophageal cancer          PB              SNPshot             444/468                     rs2910164
  11        Dou       2010     Asian               Glioma                PB                LDR               643/656                     rs11614913
  12        Li        2010     Asian                 HCC                 HB             PCR-RFLP             310/222                     rs11614913
  13       Chen       2010     Asian                 CRC                 PB                LDR               126/407                     rs11614913
  14     Pastrello    2010   Caucasian      Breast/ovarian cancer        PB             PCR-RFLP             101/155                     rs2910164
  15        Qi        2010     Asian                 HCC                 PB                LDR               361/391                     rs11614913
  16       Peng       2010     Asian           Gastric Cancer            PB             PCR-RFLP             213/213                     rs11614913
  17    Srivastava    2010     Asian         Gallbladder cancer          PB             PCR-RFLP             230/230           rs11614913,rs2910164,rs3746444
  18       Zeng       2010     Asian           Gastric Cancer            HB             PCR-RFLP             304/304                     rs2910164
  19      Catucci     2010   Caucasian          Breast Cancer            PB              Taqman             1852/2739          rs11614913,rs2910164,rs3746444
  20        Liu       2010   Caucasian      Head and neck cancer         PB             PCR-RFLP            1109/1130     rs11614913,rs2910164,rs3746444,rs2292832
  21    Christensen   2010   Caucasian      Head and neck cancer         PB              Taqman              484/555                     rs11614913
  22       Okubo      2011     Asian           Gastric Cancer            HB             PCR-RFLP             552/697           rs11614913,rs2910164,rs3746444
  23       Zhou       2011     Asian           Cervical cancer           PB             PCR-RFLP             226/309           rs11614913,rs2910164,rs3746444
  24       Akkız      2011   Caucasian               HCC                 PB             PCR-RFLP             185/185                     rs11614913
  25        Zhu       2011     Asian                 CRC                 PB              Taqman              573/588                     rs11614913
  26    Permuth-Wey   2011   Caucasian             Glioma                PB      Illumina\'s Golden Gate     593/614                     rs2910164
  27       Zhan       2011     Asian                 CRC                 HB             PCR-RFLP             252/543                     rs11614913
  28       Hong       2011     Asian             Lung Cancer             PB              Taqman              406/428                     rs11614913
  29       Zhou       2011     Asian        Primary Liver Cancer         PB             PCR-RFLP                                    rs2910164,rs3746444
  30        Min       2011     Asian                 CRC                 PB             PCR-RFLP             446/502      rs11614913,rs2910164,rs3746444,rs2292832
  31      Hishida     2011     Asian           Gastric Cancer            HB             PCR-CTPP             583/1637                    rs2910164
  32      George      2011     Asian           Prostate cancer           PB             PCR-RFLP             159/230           rs11614913,rs2910164,rs3746444
  33      Mittal      2011     Asian           Bladder Cancer            PB             PCR-RFLP             212/250           rs11614913,rs2910164,rs3746444
  34       Akkız      2011   Caucasian               HCC                 PB             PCR-RFLP             222/222                     rs2910164
  35        Yue       2011     Asian           Cervical cancer           PB             PCR-RFLP             447/443                     rs2910164
  36       Zhang      2011     Asian            Breast Cancer            PB             PCR-RFLP             248/243                rs11614913,rs2292832
  37     Jedlinski    2011   Caucasian          Breast Cancer            PB             PCR-RFLP             187/171                     rs11614913
  38       Zhou       2012     Asian           Gastric Cancer            HB              Taqman             1686/1895                    rs2910164
  39       Xiang      2012     Asian                 HCC                 PB             PCR-RFLP              100/90                rs2910164,rs3746444
  40        Kim       2012     Asian                 HCC                 PB             PCR-RFLP             159/201      rs11614913,rs2910164,rs3746444,rs2292832

HB, hospital based; PB, population based; HCC, hepatocellular carcinoma; CRC, colorectal cancer; PCR-RFLP, polymerase chain reaction--restriction fragment length polymorphism; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; LDR, ligation detection reaction.

Quantitative synthesis {#s3b}
----------------------

For rs11614913 polymorphism, significant differences were observed for the comparison of TT vs. CC and TT vs. CC+CT. When grouped by the cancer types, significant associations were still found in colorectal cancer (TT vs. CC: OR = 0.70, 95% CI: 0.57--0.85, *P* ~h~ = 0.284; TT+TC vs. CC: OR = 0.77, 95% CI: 0.65--0.91, *P* ~h~ = 0.377; TT vs. CC+TC: OR = 0.80, 95% CI: 0.69--0.94, *P* ~h~ = 0.198), lung cancer(TT vs. CC: OR = 0.77, 95% CI: 0.65--0.91, *P* ~h~ = 0.284; TT+TC vs. CC: OR = 0.85, 95% CI: 0.74--0.98, *P* ~h~ = 0.289; TT vs. CC+TC: OR = 0.83, 95% CI: 0.73--0.95, *P* ~h~ = 0.281). In addition to the decreased risk for colorectal cancer and lung cancer, a decreased risk was also observed in other cancer groups (CT vs. CC: OR = 1.23, 95% CI: 1.10--2.13, *P* ~h~ = 0.239; TT+CT vs. CC: OR = 1.13, 95% CI: 1.03--1.25, *P* ~h~ = 0.096). Subgroup analysis by the ethnicity revealed a significant association in the comparison of TT vs. CC (OR = 0.80, 95% CI: 0.73--0.88, *P* ~h~ = 0.169), and TT vs. CC+CT (OR = 0.85, 95% CI: 0.80--0.92, *P* ~h~ = 0.300) in the Asian population. Subgroup analysis determined by the source of control revealed a significant association between the polymorphism and cancer risk in both the hospital and population based controls for the comparison of TT vs. CC and TT vs. CT+CC; moreover, a decreased risk was also observed for the comparison of TT+CT vs. CC in hospital based study, as summarized in [Table 2](#pone-0049032-t002){ref-type="table"}.

10.1371/journal.pone.0049032.t002

###### Stratification analyses of genetic susceptibility of rs11614913 polymorphism to cancer risk.

![](pone.0049032.t002){#pone-0049032-t002-2}

  Category              Cases/Controls                        TT vs. CC                         CT vs. CC   TT+CT vs. CC                    TT vs. CC+CT                                                                                                                                                                       
  -------------------- ---------------- ------------------------------------------------------ ----------- -------------- ------------------------------------------------- ----------- ------ ------------------------------------------------- ------- ------ ------------------------------------------------------ ------- ------
  Total                  12663/14739     **0.83(0.74,0.93)** [b](#nt103){ref-type="table-fn"}     0.001         52.5       0.98(0.90,1.07)[b](#nt103){ref-type="table-fn"}     0.004     47.5   0.94(0.86,1.02)[b](#nt103){ref-type="table-fn"}   0.001   53.8   **0.86(0.79,0.95)** [b](#nt103){ref-type="table-fn"}   0.005   46.7
  Cancer types                                                                                                                                                                                                                                                                                                                 
  Breast cancer           3722/4712        0.81(0.61,1.09)[b](#nt103){ref-type="table-fn"}        0.014          68                        0.94(0.85,1.04)                     0.532      0                   **0.91(0.83,1.00)**                 0.148    41      0.87(0.70,1.08)[b](#nt103){ref-type="table-fn"}      0.027   63.5
  Colorectal cancer       1397/2040                      **0.70(0.57,0.85)**                      0.284         21.1                       0.81(0.65,1.08)                     0.367     5.2                  **0.77(0.65,0.91)**                 0.377   3.1                    **0.80(0.69,0.94)**                    0.198   35.7
  HCC                      1015/999        0.74(0.47,1.19)[b](#nt103){ref-type="table-fn"}        0.022          69                        0.90(0.72,1.11)                     0.631      0                     0.85(0.69,1.04)                   0.19     37      0.18(0.57,1.15)[b](#nt103){ref-type="table-fn"}      0.037   64.6
  Lung cancer             2118/2103                      **0.77(0.65,0.91)**                      0.895          0                         0.90(0.77,1.04)                     0.098      57                  **0.85(0.74,0.98)**                 0.289   19.4                   **0.83(0.73,0.95)**                    0.281   21.3
  Gastric cancer           765/910                         0.80(0.61,1.06)                        0.306         4.5                        0.84(0.65,1.08)                     0.163     48.5                   0.82(0.65,1.04)                   0.162   48.8                     0.89(0.72,1.11)                      0.698    0
  Other cancers           3646/3975                        1.06 (0.91,1.23)                       0.125         38.2                     **1.23(1.10,1.37)**                 **0.239**   23.9                 **1.13(1.03,1.25)**                 0.096   40.7                     0.93(0.74,1.17)                      0.024   56.7
  Ethnicities                                                                                                                                                                                                                                                                                                                  
  Asian                   7837/8878                      **0.80(0.73,0.88)**                      0.169         23.7       0.99(0.88,1.13)[b](#nt103){ref-type="table-fn"}     0.001     57.4   0.95(0.84,1.07)[b](#nt103){ref-type="table-fn"}   0.001   58.3                   **0.85(0.80,0.92)**                     0.3    12.6
  Caucasian               4400/5395        0.94(0.71,1.23)[b](#nt103){ref-type="table-fn"}        0.006         69.7       1.01(0.92,1.04)[b](#nt103){ref-type="table-fn"}     0.597      0                     0.98(0.90,1.07)                   0.181   32.3     0.94(0.74,1.21)[b](#nt103){ref-type="table-fn"}      0.005   70.5
  Source of controls                                                                                                                                                                                                                                                                                                           
  Population based       11123/12811     **0.87(0.77,0.98)** [b](#nt103){ref-type="table-fn"}     0.009         46.7       1.01(0.91,1.11)[b](#nt103){ref-type="table-fn"}     0.002     52.4   0.97(0.88,1.06)[b](#nt103){ref-type="table-fn"}   0.001   54.8   **0.89(0.82,0.98)** [b](#nt103){ref-type="table-fn"}   0.024   41.1
  Hospital based          1540/1928                      **0.65(0.53,0.79)**                      0.111          50                        0.85(0.72,1.01)                     0.868      0                  **0.78 (0.67,0.92)**                 0.585    0                     **0.74(0.63,0.87)**                    0.092   53.5

P value of Q-test for heterogeneity test.

Random-effects model was used when a P value\<0.05 for heterogeneity test; otherwise, fixed-effects model was used.

*I* ^2^: 0--25, no heterogeneity; 25--50, modest heterogeneity; 50, high heterogeneity.

For the rs2910164 polymorphism, no significant risk association was observed in the overall pooled analysis. However, cancer type-subgroup analysis revealed a decreased risk for the comparison of CC vs. GG in the subgroup of HCC (OR = 0.76, 95% CI: 0.59--0.99, *P* ~h~ = 0.313), prostate cancer (OR = 0.77, 95% CI: 0.65--0.91, *P* ~h~ = 0.425), cervical cancer (OR = 0.50, 95% CI: 0.37--0.68, *P* ~h~ = 0.814) and esophageal cancer (OR = 0.58, 95% CI: 0.37--0.90, *P* ~h~ = 0.055). Similarly, a decreased risk was observed for the comparison of GC vs. GG in the cervical cancer (OR = 0.71, 95% CI: 0.51--0.99, *P* ~h~ = 0.254), CC+GC vs. GG in esophageal cancer (OR = 0.79, 95% CI: 0.65--0.96, *P* ~h~ = 0.195), and CC vs. GG+GC in prostate cancer (OR = 0.65, 95% CI: 0.44--0.96, *P* ~h~ = 0.699) and esophageal cancer (OR = 0.64, 95% CI: 0.41--0.98, *P* ~h~ = 0.079). Subgroup analysis by ethnicity revealed a decreased risk in the Asian population (CC vs. GG: OR = 0.80, 95% CI: 0.67--0.96, *P* ~h~ = 0.000; GC vs. GG: OR = 0.91, 95% CI: 0.84--0.98, *P* ~h~ = 0.139; CC+GC vs. GG: OR = 0.88, 95% CI: 0.79--0.99, *P* ~h~ = 0.002; CC vs. GG+GC: OR = 0.86, 95% CI: 0.76--0.98, *P* ~h~ = 0.000) but not Caucasian population. A decreased risk was also observed for the comparison of CC vs. GG in both studies based population (OR = 0.87, 95% CI: 0.77--0.98, *P* ~h~ = 0.000) and hospital based controls (OR = 0.65, 95% CI: 0.53--0.79, *P* ~h~ = 0.000) when performed subgroup analysis by the source of controls. In contrast, an increased risk was also observed in the other cancers group for the comparison of CC+GC vs. GG (OR = 1.09, 95% CI: 1.00--1.19, Z = 2.02, *P* = 0.043, *P* ~h~ = 0.222) as summarized in [Table 3](#pone-0049032-t003){ref-type="table"}.

10.1371/journal.pone.0049032.t003

###### Stratification analyses of genetic susceptibility of rs2910164 polymorphism to cancer risk.
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  Category              cases/controls                        CC vs. GG                         GC vs. GG   CC+GC vs. GG                    CC vs. GG+GC                                                                                                                                                                   
  -------------------- ---------------- ------------------------------------------------------ ----------- -------------- ------------------------------------------------- ------- ------ ------------------------------------------------- ------- ------ ------------------------------------------------------ ------- ------
  Total                  13751/16838       0.88(0.75,1.03)[b](#nt106){ref-type="table-fn"}          0            68        0.98(0.90,1.06)[b](#nt106){ref-type="table-fn"}   0.005   46.4   0.94(0.86,1.02)[b](#nt106){ref-type="table-fn"}     0     58.7     0.91(0.81,1.02)[b](#nt106){ref-type="table-fn"}        0     63.9
  Cancer types                                                                                                                                                                                                                                                                                                             
  HCC                     1146/1500                      **0.76(0.59,0.99)**                      0.313         15.9                       0.92(0.70,1.21)                   0.208    0                     0.87(0.71,1.07)                   0.169   37.9                     0.88(0.74,1.05)                      0.371   6.3
  Gastric cancer          3125/4533        0.92(0.63,1.34)[b](#nt106){ref-type="table-fn"}          0           84.1                       0.96(0.79,1.16)                   0.136   45.8                   0.96(0.74,1.24)                   0.011   73.1     0.92(0.70,1.21)[b](#nt106){ref-type="table-fn"}        0     83.5
  Breast cancer           3007/3718                        1.11(0.93,1.33)                        0.497          0                        1.01 (0.90,1.11)                   0.538    0                     1.03(0.93,1.14)                   0.587    0                       1.06(0.92,1.23)                      0.331   9.6
  Prostate cancer          410/510                       **0.77(0.65,0.91)**                      0.425          0                         0.90(0.58,1.41)                   0.131   56.1                   0.97(0.92,1.02)                   0.062   71.4                   **0.65(0.44,0.96)**                    0.699    0
  Cervical cancer          673/752                       **0.50(0.37,0.68)**                      0.814          0                       **0.71(0.51,0.99)**                 0.254   23.1                   0.82(0.65,1.04)                   0.382    0                       0.65(0.72,1.11)                      0.359    0
  Esophageal cancer        772/779                       **0.58(0.37,0.90)**                      0.055         72.9                       0.82(0.66,1.01)                   0.406    0                   **0.79(0.65,0.96)**                 0.195   40.4                   **0.64(0.41,0.98)**                    0.079   67.6
  Other cancers           4618/5046        1.06 (0.81,1.40)[b](#nt106){ref-type="table-fn"}       0.021         55.6                       1.07(0.94,1.22)                   0.05    48.3                   1.09(1.00,1.19)                   0.222   24.9     1.03(0.77,1.36)[b](#nt106){ref-type="table-fn"}      0.003   65.5
  Ethnicities                                                                                                                                                                                                                                                                                                              
  Asian                   8531/10645     **0.80(0.67,0.96)** [b](#nt106){ref-type="table-fn"}       0            69                      **0.91(0.84,0.98)**                 0.139   27.1               **0.88(0.79,0.99)** ^c^               0.002   55.5   **0.86(0.76,0.98)** [b](#nt106){ref-type="table-fn"}     0     62.9
  Caucasian               4781/5715        1.06(0.79,1.43)[b](#nt106){ref-type="table-fn"}        0.027         55.6       1.07(0.93,1.22)[b](#nt106){ref-type="table-fn"}   0.03     55                    1.07(0.99,1.16)                   0.243   23.4     1.03(0.74,1.44)[b](#nt106){ref-type="table-fn"}      0.005   65.9
  Source of controls                                                                                                                                                                                                                                                                                                       
  Population based       10187/11827     **0.87(0.77,0.98)** [b](#nt106){ref-type="table-fn"}       0           65.3       0.97(0.88,1.06)[b](#nt106){ref-type="table-fn"}   0.008   47.1   0.95(0.86,1.04)[b](#nt106){ref-type="table-fn"}   0.001   55.1     0.89(0.78,1.03)[b](#nt106){ref-type="table-fn"}        0     78.8
  Hospital based          3564/5011      **0.65(0.53,0.79)** [b](#nt106){ref-type="table-fn"}       0           80.6                       0.99(0.93,1.06)                   0.089   50.5   1.00(0.80,1.25)[b](#nt106){ref-type="table-fn"}   0.005   73.2     0.95(0.74,1.21)[b](#nt106){ref-type="table-fn"}      0.001   60.3

P value of Q-test for heterogeneity test.

Random-effects model was used when a P value\<0.05 for heterogeneity test; otherwise, fixed-effects model was used.

*I* ^2^: 0--25, no heterogeneity; 25--50, modest heterogeneity; 50, high heterogeneity.

For the rs3746444 polymorphism, there was no significant risk association observed for the overall pooled analysis of cancer risk. However, increased risks were observed for GG vs. AA (OR = 1.23, 95% CI: 1.00--1.50, Z = 2.00, *P* = 0.045, *P* ~h~ = 0.118), GA vs. AA (OR = 1.19, 95% CI: 1.01--1.41, *P* ~h~ = 0.001) and CC+GC vs. GG (OR = 1.14, 95% CI: 1.05--1.25, *P* ~h~ = 0.003) in the Asian population rather than in the Caucasian population summarized in [Table 4](#pone-0049032-t004){ref-type="table"}. For the rs2292832, there was no significant association observed in all comparisons (data not shown).

10.1371/journal.pone.0049032.t004

###### Stratification analyses of genetic susceptibility of rs3746444 polymorphism to cancer risk.
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  Category         cases/controls                      GG vs. AA                      GA vs. AA   GG+GA vs. AA                       GG vs. GA+AA                                                                                                                                                                    
  --------------- ---------------- ------------------------------------------------- ----------- -------------- ------------------------------------------------------ ------- ------ ------------------------------------------------------ ------- ------ ------------------------------------------------- ------ ------
  Total              7025/8427                      1.11(0.95,1.29)                     0.127          32          1.12(0.97,1.29)[b](#nt109){ref-type="table-fn"}        0     69.8     1.12(0.98,1.28)[b](#nt109){ref-type="table-fn"}        0     68.2                   1.06(0.91,1.23)                   0.07   39.1
  Cancer types                                                                                                                                                                                                                                                                                                       
  HCC                 445/784       1.25(0.36,4.34)[b](#nt109){ref-type="table-fn"}     0.023         73.6         1.00(0.76,1.31)[b](#nt109){ref-type="table-fn"}      0.074   61.6     1.12(0.63,1.99)[b](#nt109){ref-type="table-fn"}      0.009   78.8                   1.51(0.87,2.62)                   0.06    64
  Breast cancer      2588/3260      1.26(0.70,2.26)[b](#nt109){ref-type="table-fn"}     0.036         77.2                         1.07 (0.95,1.20)                     0.163   48.6                     1.08(0.97,1.20)                      0.056   72.7                   1.11(0.87,1.42)                   0.05    74
  Other cancers      3992/4383                      1.06(0.85,1.28)                     0.795          0           1.17(0.94,1.46) [b](#nt109){ref-type="table-fn"}       0     78.4     1.14(0.95,1.36)[b](#nt109){ref-type="table-fn"}      0.001   71.2                   0.98(0.80,1.20)                   0.31   15.4
  Ethnicities                                                                                                                                                                                                                                                                                                        
  Asian              4337/5130                    **1.23(1.00,1.50)**                   0.118          35        **1.19(1.01,1.41)** [b](#nt109){ref-type="table-fn"}   0.001    65    **1.14(1.05,1.25)** [b](#nt109){ref-type="table-fn"}   0.003   62.1   1.08(0.81,1.44)[b](#nt109){ref-type="table-fn"}   0.04   47.2
  Caucasian          2688/3297                      0.97(0.76,1.22)                     0.97           0                           0.93(0.83,1.04)                      0.053   73.2                     0.92(0.76,1.11)                      0.083   66.8                   0.99(0.78,1.24)                   0.74    0

P value of Q-test for heterogeneity test.

Random-effects model was used when a P value\<0.05 for heterogeneity test; otherwise, fixed-effects model was used.

*I* ^2^: 0--25, no heterogeneity; 25--50, modest heterogeneity; 50 high heterogeneity.

Test of heterogeneity {#s3c}
---------------------

There was significant heterogeneity across the studies of the rs11614913, rs2910164, rs3746444, and thus the source of heterogeneity was further explored by the heterozygote comparison. For the rs11614913, cancer type (χ2 = 23.68, df = 5, *P* = 0.000) and source of control (χ2 = 5.63, df = 1, *P* = 0.018) were the source of the heterogeneity. For rs2910164 polymorphism, cancer type (χ2 = 27.65, df = 6, *P* = 0.000) and ethnicity (χ2 = 15.52, df = 3, *P* = 0.000) contributed substantially to the heterogeneity. For the rs3746444 polymorphism, ethnicity (χ2 = 8.38, df = 1, *P* = 0.004) contributed substantially to heterogeneity.

Sensitivity analysis revealed that the four independent studies [@pone.0049032-Dou1], [@pone.0049032-Srivastava1], [@pone.0049032-George1], [@pone.0049032-Mittal1] were the main cause of heterogeneity for the rs11614913. Heterogeneity was decreased when these studies were removed (TT+CT vs. CC: *P* ~h~ = 0.061, *I* ^2^ = 33.49%). Similarly, heterogeneity of the rs2910164 (CC+GC vs. GG: *P* ~h~ = 0.060, *I* ^2^ = 33.5%) and rs3746444 (GG+GA vs. AA: *P* ~h~ = 0.092, *I* ^2^ = 39.8%) were decreased when the four [@pone.0049032-Xu2], [@pone.0049032-Jazdzewski1], [@pone.0049032-Okubo1], [@pone.0049032-Zhou1] and the three [@pone.0049032-George1], [@pone.0049032-Zhou2], [@pone.0049032-Xiang1] independent studies removed, respectively.

Publication bias {#s3d}
----------------

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of the currently available literature. The shape of the funnel plots did not reveal any evidence of obvious asymmetry in all comparison models. Then, the Egger\'s test was used to provide statistical evidence for funnel plot symmetry. The results also did not show any evidence of publication bias (rs11614913: *t* = 0.25, *P* =  0.806, rs2910164: *t* = −0.70, *P* = 0.489, rs37464444: *t* = 1.88, *P* = 0.087, and rs2292832: *t* = 1.14, *P* = 0.318 for dominant model. [Figure 1](#pone-0049032-g001){ref-type="fig"}).

![Begg\'s funnel plot for publication bias test.\
Each circle denotes an independent study for the indicated association. Log\[OR\], natural logarithm of OR. Horizontal line stands for mean effect size. A: rs11614913, B: rs2910164, C: rs37464444, D: rs2292832.](pone.0049032.g001){#pone-0049032-g001}

Discussion {#s4}
==========

In this meta-analysis, an association between the four common SNPs in microRNAs (rs11614913, rs2910164, rs3746444, and rs2292832) and cancer risk was evaluated by the pooled results from 40 published studies. The results demonstrated that the rs11614913TT genotype was associated with a decreased risk for developing cancer, in particular for colorectal cancer and lung cancer, or in the Asian population, and that the rs2910164C allele was associated with a decreased risk for developing esophageal cancer, cervical cancer, prostate cancer and HCC, in particular in the Asian population. Contrary to the above, the rs3746444G allele was observed as a risk factor for cancer in the Asian population; however, the rs2292832 polymorphism was not associated with cancer risk.

The rs11614913 polymorphism present in the miR-196a2 has significantly greater impact on miR-196a expression and is associated with various carcinogenesis [@pone.0049032-Hu1], [@pone.0049032-Zhan1], [@pone.0049032-Li1]. Although there were studies reporting no direct association between rs11614913 and the expression of miR-196a [@pone.0049032-Christensen1], [@pone.0049032-Hoffman1], previous, meta-analysis studies have suggested an association between rs11614913 and risk of cancers [@pone.0049032-Xu1], [@pone.0049032-Wang1], [@pone.0049032-Chu1], [@pone.0049032-Qiu1], This updated meta-analysis further support the rs11614913 TT genotype was associated with a decreased risk for cancer. In addition, significant associations were observed in the Asian population but not in the Caucasian population, suggesting a possible ethnic difference in the genetic background and the environment, which was the similar to that reported by Chu et al [@pone.0049032-Chu1] and Wang et al [@pone.0049032-Wang1]. In contrast to the published pooled results, this updated pooled results revealed that the rs116114913 TT could be a protective factor against colorectal cancer and lung cancer. However, no significant association was observed in breast cancer, suggesting that carcinogenic mechanisms may differ in the tumor sites and hsa-miR-196a2 genetic variants.. The risk of different cancer types should be confirmed by more studies.

For the rs2910164, no significant association was observed in overall pooled results, as supported by the report by Xu et al [@pone.0049032-Xu1]. In contrast to the published results, this study revealed the different association between rs2910164 polymorphism and cancer risk among ethnicity and the cancer types. The rs2910164 CC genotype was associated with decreased risk for esophageal cancer, cervical cancer, prostate cancer, and HCC in the Asian population, suggesting a difference in genetic background and the environment, and pathogenesis of different tumor sites. The rs2910164 in the miR-146aG\>C gene is located in the stem region opposite to the mature miR-146 sequence and results in a change from G∶U pair to C∶U mismatch in the stem structure of miR-146a precursor. It has been reported that the G-allelic miR-146a precursor could increase the production of mature miR-146a and affecting target mRNA binding [@pone.0049032-Xu2], [@pone.0049032-Jazdzewski1].

The rs3746444 polymorphism present in the miR-499 would target to SOX6 and Rod1 genes important roles for the etiology of cancers [@pone.0049032-Qi1], [@pone.0049032-Tano1]. The pooled results from 13 studies revealed that rs3746444G allele was associated with an increased risk for developing cancer in the Asian population. To our knowledge, this is the first meta-analysisabout the association of rs3746444 of cancer from 11 Asian population studies and two Caucasian population studies. More studies should be accumulated to confirm the results. The rs2292832 polymorphism has also been evaluated by six enrolled studies, with no significant associations were found from all pooled results. Thus far, few epidemiologic studies have investigated the association of rs2292832 polymorphism and cancer risk.

The heterogeneity were observed across the studies for the polymorphisms of rs11614913, rs2910164, rs3746444, the source of the heterogeneity were mainly from the cancer type, such as glioma, gallbladder, bladder, and papillary thyroid carcinoma and cervical cancer, suggesting polymorphisms in miRNAs may play different roles according the cancer type. Furthermore, different risk of polymorphisms in miRNAs was also the source of the heterogeneity, significant associations were observed in the most studies for Asian populations. The studies based on different source of control were also the source of the heterogeneity of studies.

Although meta-analysis is robust, our study still has some limitations. First, our meta-analysis did not evaluate any potential gene-gene interaction and gene-environment interaction due to lack of relevant published data. Second, although all eligible studies were summarized, the relatively small sample size of studies may lead to reduced statistical power when stratified according to the tumor type, ethnicity or infection status. Last, relatively large heterogeneity was observed across the all studies involved.

In summary, this meta-analysis suggested that the rs11614913TT genotype was associated with a decreased cancer risk, especially for colorectal cancer and lung cancer, that the rs2910164C allele was a protective factor for esophageal cancer, cervical cancer, prostate cancer and HCC, and that the rs11614913, rs2910164, and rs3746444 SNPs were risk factors for cancer in the Asian population.
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